PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials

E-ISSN： 1873-5592|19|1|21-37

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.1, 2018-01, pp. : 21-37

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel: An Update of its Use in the Treatment of Metastatic Breast Cancer and Ovarian and Other Gynaecological Cancers

By Wiseman L.R. Spencer C.M.

Drugs & Aging, Vol. 12, Iss. 4, 1998-04 ,pp. : 305-334

Adis International

Access to resources Recommend Favorite

Current treatment and clinical trials in ovarian cancer

By Han Liz Y Kipps Emma Kaye Stan B

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 4, 2010-04 ,pp. : 521-534

Informa Healthcare

Access to resources Recommend Favorite

Parp Inhibitors for the Treatment of Ovarian Cancer

Current Cancer Drug Targets, Vol. 18, Iss. 9, 2018-11 ,pp. : 877-893

Bentham Science Publishers

Access to resources Recommend Favorite

Olaparib, PARP1 inhibitor in ovarian cancer

By Marchetti Claudia Imperiale Ludovica Gasparri Maria Luisa Palaia Innocenza Pignata Sandro Boni Terenzio Bellati Filippo Benedetti Panici Pierluigi

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1575-1584

Informa Healthcare

Access to resources Recommend Favorite

Optimising Treatment of Elderly Patients with Ovarian Cancer: Improving Their Enrolment in Clinical Trials

By Jeannine Villella

Drugs & Aging, Vol. 22, Iss. 2, 2005-01 ,pp. : 95-100

Adis International

Access to resources Recommend Favorite